Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)
China
· Delayed Price · Currency is CNY 110.34
-0.98 (-0.88%)
Dec 5, 2025, 3:00 PM CST
SHA:688266 Revenue
Suzhou Zelgen Biopharmaceuticals had revenue of 217.79M CNY in the quarter ending September 30, 2025, with 51.85% growth. This brings the company's revenue in the last twelve months to 742.28M, up 51.97% year-over-year. In the year 2024, Suzhou Zelgen Biopharmaceuticals had annual revenue of 532.95M with 37.91% growth.
Revenue (ttm)
742.28M
Revenue Growth
+51.97%
P/S Ratio
39.35
Revenue / Employee
815.69K
Employees
910
Market Cap
29.21B
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 30.98B |
| WuXi AppTec | 43.88B |
| Shenzhen Mindray Bio-Medical Electronics | 33.07B |
| Sichuan Biokin Pharmaceutical | 2.23B |
| Aier Eye Hospital Group | 22.17B |
| Shanghai United Imaging Healthcare | 12.20B |
| Zhangzhou Pientzehuang Pharmaceutical., | 9.78B |
| Yunnan Baiyao Group Co.,Ltd | 40.77B |